Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 23
1990 42
1991 81
1992 125
1993 136
1994 130
1995 171
1996 193
1997 140
1998 150
1999 149
2000 150
2001 126
2002 102
2003 119
2004 109
2005 145
2006 116
2007 111
2008 99
2009 83
2010 61
2011 68
2012 51
2013 45
2014 44
2015 29
2016 26
2017 21
2018 12
2019 16
2020 24
2021 13
2022 17
2023 18
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

2,866 results

Results by year

Filters applied: . Clear all
Page 1
Didanosine.
Shelton MJ, O'Donnell AM, Morse GD. Shelton MJ, et al. Ann Pharmacother. 1992 May;26(5):660-70. doi: 10.1177/106002809202600511. Ann Pharmacother. 1992. PMID: 1350471 Review.
OBJECTIVE: To review the chemistry, intracellular metabolism, pharmacokinetics, and clinical experience with didanosine (2',3'-dideoxyinosine [ddI]). DATA SOURCES: English-language articles and conference proceedings (indexing terms were didanosine, 2',3'-dideoxyino …
OBJECTIVE: To review the chemistry, intracellular metabolism, pharmacokinetics, and clinical experience with didanosine (2',3'-dideox …
DIDANOSINE RETINAL TOXICITY.
Haug SJ, Wong RW, Day S, Choudhry N, Sneed S, Prasad P, Read S, McDonald RH, Agarwal A, Davis J, Sarraf D. Haug SJ, et al. Retina. 2016 Dec;36 Suppl 1:S159-S167. doi: 10.1097/IAE.0000000000001267. Retina. 2016. PMID: 28005674
A literature review was also performed to collect all reported cases of chorioretinal degeneration secondary to didanosine toxicity. RESULTS: Nine patients were identified who had findings consistent with peripheral retinal toxicity secondary to didanosine use. ...A …
A literature review was also performed to collect all reported cases of chorioretinal degeneration secondary to didanosine toxicity. …
Didanosine, a new antiretroviral drug. A review.
Franssen RM, Meenhorst PL, Koks CH, Beijnen JH. Franssen RM, et al. Pharm Weekbl Sci. 1992 Oct 16;14(5):297-304. doi: 10.1007/BF01977617. Pharm Weekbl Sci. 1992. PMID: 1437513 Review.
In this article the literature about didanosine, an antiretroviral drug, is reviewed. The mechanism of action, biochemical pharmacology, pharmacokinetics, and clinical results of phase-I trials are discussed. ...An antiretroviral effect was observed in terms of an increase …
In this article the literature about didanosine, an antiretroviral drug, is reviewed. The mechanism of action, biochemical pharmacolo …
Didanosine: an updated review of its use in HIV infection.
Perry CM, Noble S. Perry CM, et al. Drugs. 1999 Dec;58(6):1099-135. doi: 10.2165/00003495-199958060-00009. Drugs. 1999. PMID: 10651392 Review.
Didanosine, like zidovudine, stavudine and lamivudine, is a nucleoside analogue reverse transcriptase inhibitor (NRTI). ...Combination therapy with didanosine and zidovudine delays disease progression and prolongs survival in patients with intermediate or advanced H
Didanosine, like zidovudine, stavudine and lamivudine, is a nucleoside analogue reverse transcriptase inhibitor (NRTI). ...Combinatio
Zalcitabine and didanosine.
Lipsky JJ. Lipsky JJ. Lancet. 1993 Jan 2;341(8836):30-2. doi: 10.1016/0140-6736(93)92496-g. Lancet. 1993. PMID: 8093278 Review. No abstract available.
Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.
Moreno S, Hernández B, Dronda F. Moreno S, et al. Drugs. 2007;67(10):1441-62. doi: 10.2165/00003495-200767100-00006. Drugs. 2007. PMID: 17600392 Review.
Didanosine may select for resistance mutations that may render the drug inactive against the virus; L74V and K65R remain as the main didanosine-related mutations. ...The administration of didanosine to treatment-experienced patients has been evaluated in two
Didanosine may select for resistance mutations that may render the drug inactive against the virus; L74V and K65R remain as the main
Update on didanosine.
Cooper DA. Cooper DA. J Int Assoc Physicians AIDS Care (Chic). 2002 Winter;1(1):15-25. doi: 10.1177/154510970200100105. J Int Assoc Physicians AIDS Care (Chic). 2002. PMID: 12942665 Review.
Didanosine (ddl) has been a cornerstone of HIV management since it was made available in October 1991. Didanosine was originally introduced as an alternative to zidovudine (ZDV) for patients who were intolerant of ZDV or experienced disease progression during ZDV mo
Didanosine (ddl) has been a cornerstone of HIV management since it was made available in October 1991. Didanosine was original
[Didanosine].
[No authors listed] [No authors listed] Enferm Infecc Microbiol Clin. 1995 Oct;13(8):487-90. Enferm Infecc Microbiol Clin. 1995. PMID: 8555311 Review. Spanish. No abstract available.
Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.
Perry CM, Balfour JA. Perry CM, et al. Drugs. 1996 Dec;52(6):928-62. doi: 10.2165/00003495-199652060-00014. Drugs. 1996. PMID: 8957161 Review.
Didanosine has a tolerability profile that is distinctly different from that of zidovudine. ...The most serious dose-limiting adverse effects associated with didanosine treatment are peripheral neuropathy and pancreatitis. In conclusion, didanosine monotherap
Didanosine has a tolerability profile that is distinctly different from that of zidovudine. ...The most serious dose-limiting adverse
Didanosine once daily: potential for expanded use.
Pollard RB. Pollard RB. AIDS. 2000 Nov 10;14(16):2421-8. doi: 10.1097/00002030-200011100-00002. AIDS. 2000. PMID: 11101051 Review.
However, the active metabolite of didanosine (2',3'-dideoxyadenosine-5'-triphosphate) has a long intracellular half-life that supports the use of didanosine in a more patient-friendly, once-daily dosing schedule. ...Preliminary results from recent studies support th …
However, the active metabolite of didanosine (2',3'-dideoxyadenosine-5'-triphosphate) has a long intracellular half-life that support …
2,866 results